Pectasides D, Psyrri A, Pectasides M, Economopoulos T
Second Department of Internal Medicine, Athens University, Attikon University Hospital, Rimini 1, Haidari, Athens, Greece.
Expert Opin Pharmacother. 2006 Jun;7(8):975-87. doi: 10.1517/14656566.7.8.975.
Ovarian cancer is more fatal than all the other gynaecological malignancies combined. Although most patients respond to first-line combination chemotherapy, the vast majority (50-75%) of patients with advanced disease will relapse. The management of patients with recurrent ovarian cancer is based on their response profile to platinum: patients with platinum-sensitive disease can be rechallenged with platinum-based chemotherapy, whereas the management of patients with platinum-resistant or -refractory disease remains an area of active investigation. In this review, the data for second-line therapy in this latter group of patients will be summarised and recommendations for their optimal management will be made.
卵巢癌比所有其他妇科恶性肿瘤加起来更具致命性。尽管大多数患者对一线联合化疗有反应，但绝大多数（50%-75%）晚期疾病患者会复发。复发性卵巢癌患者的治疗基于其对铂类药物的反应情况：铂类敏感疾病患者可再次接受铂类化疗，而铂类耐药或难治性疾病患者的治疗仍是一个积极研究的领域。在本综述中，将总结后一组患者二线治疗的数据，并对其最佳管理提出建议。
